精华制药
(002349)
| 流通市值：61.14亿 | | | 总市值：62.31亿 |
| 流通股本：8.14亿 | | | 总股本：8.30亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 731,420,574.35 | 363,535,559.83 | 1,402,088,293.43 | 1,045,172,312.93 |
| 营业收入 | 731,420,574.35 | 363,535,559.83 | 1,402,088,293.43 | 1,045,172,312.93 |
| 二、营业总成本 | 558,016,042.71 | 279,284,981.39 | 1,110,157,028.28 | 825,883,624.7 |
| 营业成本 | 339,310,270.71 | 175,127,814.59 | 705,568,874.92 | 523,962,973.54 |
| 税金及附加 | 11,739,390.83 | 5,690,601.14 | 20,823,343.48 | 15,466,427.8 |
| 销售费用 | 132,274,180.08 | 62,075,019.03 | 247,794,237.97 | 183,281,978.47 |
| 管理费用 | 57,664,195.89 | 30,642,077 | 118,929,822.02 | 86,850,764.65 |
| 研发费用 | 28,840,794.78 | 10,499,381.03 | 61,789,405.41 | 47,149,976.95 |
| 财务费用 | -11,812,789.58 | -4,749,911.4 | -44,748,655.52 | -30,828,496.71 |
| 其中:利息费用 | 461,853.97 | 228,985.49 | 1,335,484.11 | 2,068,573.35 |
| 其中:利息收入 | 12,852,938.48 | 5,101,522.93 | 44,008,856.13 | 33,683,811.02 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,451,220.5 | 782,312.56 | 3,816,186.27 | 3,657,354.18 |
| 加:投资收益 | 1,434,037.28 | 472,032.72 | 4,372,311.26 | 1,944,009.37 |
| 资产处置收益 | 28,384.68 | 23,905.98 | -202,291.53 | 3,154.45 |
| 资产减值损失(新) | -4,097,935.86 | -3,776,994.23 | -15,257,525.46 | -974,977.34 |
| 信用减值损失(新) | -829,088.08 | -518,188.18 | -3,404,161.92 | -2,019,687.02 |
| 其他收益 | 2,783,496.78 | 1,517,110.64 | 13,802,514.57 | 7,038,178.48 |
| 四、营业利润 | 174,174,646.94 | 82,750,757.93 | 295,058,298.34 | 228,936,720.35 |
| 加:营业外收入 | 987,323.68 | 760,227.89 | 3,199,057.13 | 226,024.34 |
| 减:营业外支出 | 26,870.12 | 1,154.91 | 4,939,013.38 | 3,953,336.64 |
| 五、利润总额 | 175,135,100.5 | 83,509,830.91 | 293,318,342.09 | 225,209,408.05 |
| 减:所得税费用 | 23,448,502.07 | 11,992,395.52 | 45,852,077.23 | 34,700,369.71 |
| 六、净利润 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 | 190,509,038.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 | 190,509,038.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 130,644,421.69 | 62,219,690.39 | 212,651,534.66 | 164,234,071.15 |
| 少数股东损益 | 21,042,176.74 | 9,297,745 | 34,814,730.2 | 26,274,967.19 |
| 扣除非经常损益后的净利润 | 126,621,740.94 | 60,349,142.87 | 195,897,114.5 | 155,827,389.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.08 | 0.26 | 0.2 |
| (二)稀释每股收益 | 0.16 | 0.08 | 0.26 | 0.2 |
| 九、综合收益总额 | 151,686,598.43 | 71,517,435.39 | 247,466,264.86 | 190,509,038.34 |
| 归属于母公司股东的综合收益总额 | 130,644,421.69 | 62,219,690.39 | 212,651,534.66 | 164,234,071.15 |
| 归属于少数股东的综合收益总额 | 21,042,176.74 | 9,297,745 | 34,814,730.2 | 26,274,967.19 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-15 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |